The FDA has announced that Eli Lilly's Zepbound and Mounjaro are now available in the US after shortages.

• The U.S. Food and Drug Administration's drug shortage database has announced that all doses of Eli Lilly's weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S.
• Eli Lilly CEO David Ricks stated that the shortages of Mounjaro and Zepbound would end "very soon."
• The demand for weight loss and diabetes drugs has exceeded supply for months, prompting Eli Lilly and Novo Nordisk to invest billions to increase production.

The highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., as per an update on the U.S. Food and Drug Administration's drug shortage database on Friday.

Since 2022, some doses of Mounjaro have been in shortage, while doses of Zepbound joined the FDA's shortage list earlier this year following its U.S. approval in November.

The demand for weight loss and diabetes drugs has exceeded supply for several months, prompting Eli Lilly and its competitors to invest billions to increase production.

The FDA has issued an update on the shortages of Mounjaro and Zepbound, one day after Eli Lilly CEO David Ricks stated that the shortages would end "very soon."

He informed the outlet in an interview that he planned to exit the process either today or tomorrow.

Eli Lilly did not respond to CNBC's request for comment on the FDA's update on Friday.

As of Friday, all doses of Novo Nordisk's diabetes injection Ozempic are available in the U.S., according to the FDA's database. However, the FDA stated that some doses of Novo Nordisk's weight loss drug Wegovy have a limited supply.